CA2295140A1 - Stable insulin formulations - Google Patents
Stable insulin formulations Download PDFInfo
- Publication number
- CA2295140A1 CA2295140A1 CA002295140A CA2295140A CA2295140A1 CA 2295140 A1 CA2295140 A1 CA 2295140A1 CA 002295140 A CA002295140 A CA 002295140A CA 2295140 A CA2295140 A CA 2295140A CA 2295140 A1 CA2295140 A1 CA 2295140A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- insulin analog
- monomeric insulin
- tris
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
Claims (28)
1. A solution formulation comprising:
a physiologically tolerated buffer selected from the group consisting of TRIS and arginine; a monomeric insulin analog;
zinc; and a phenolic preservative.
a physiologically tolerated buffer selected from the group consisting of TRIS and arginine; a monomeric insulin analog;
zinc; and a phenolic preservative.
2. The formulation of Claim 1, wherein the monomeric insulin analog is LysB28ProB29-human insulin and the buffer is TRIS.
3. The formulation of Claim 1, wherein the monomeric insulin analog is AspB28-human insulin and the buffer is TRIS.
4. The formulation of Claim 2 further comprising an isotonicity agent and wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22°C.
5. The formulation of Claim 4, wherein the concentration of LysB28ProB29_human insulin is between about 100 and about 400 units per milliliter.
6. The formulation of Claim 5, wherein TRIS is present at a concentration of about 2 mg/mL; glycerol is the isotonicity agent and is present at a concentration of about 16 mg/mL; and m-cresol is present at a concentration of about 1.76 mg/mL and phenol is present at a concentration of about 0.715 mg/mL.
7. A stable, soluble formulation of a monomeric insulin analog for use in a continuous infusion system, consisting essentially of: an isotonicity agent; a buffer selected from the group consisting of TRIS and arginine; a monomeric insulin analog; zinc; and a phenolic preservative.
8. The insulin analog formulation of Claim 1 which further comprises protamine.
9. The formulation of Claim 8, wherein the insulin analog is LysB28ProB29,
10. The formulation of Claim 8, wherein the insulin analog is AspB28.
11. The formulation of any one of Claims 8 through 10 wherein the buffer is arginine.
12. The formulation of any one of Claims 1 through 7 for use in a continuous infusion system.
13. A method for treating diabetes comprising administering an effective dose of the formulation of any one of Claims 1 through 11 to a patient in need thereof.
14. A method for treating diabetes comprising administering an effective dose of the formulation of any, one of Claims 1 through 7, wherein the formulation is administered using a continuous infusion system.
15. A method for treating hyperglycemia comprising administering an effective dose of the formulation of any one of Claims 1 through 11 to a patient in need thereof.
16. A method for treating hyperglycemia comprising administering an effective dose of the formulation of any one of Claims 1 through 7, wherein the formulation is administered using a continuous infusion system.
17. The formulation of monomeric insulin analog as described in any one of Claims 1 through 11 for use as a medicament for the treatment of diabetes.
18. The formulation of monomeric insulin analog as described in any one of Claims 1 through 11 for use as a medicament for the treatment of hyperglycemia.
19. A formulation of monomeric insulin analog as hereinbefore described with reference to any one of the examples.
20. A process for preparing the monomeric insulin analog formulation of Claim 1 comprising the steps of mixing a physiologically-tolerated buffer selected from the group consisting of TRIS and arginine with a monomeric insulin analog; zinc; and a phenolic preservative.
21. The process of Claim 20, wherein the monomeric insulin analog is LysB28ProB29-human insulin and the buffer is TRIS.
22. The process of Claim 20, wherein the monomeric insulin analog is AspB28-human insulin and the buffer is TRIS.
23. A process for preparing a monomeric insulin analog formulation comprising the steps of mixing a buffer selected from the group consisting of TRIS and arginine with a monomeric insulin analog; zinc; protamine; and a phenolic preservative.
24. The process of Claim 23, wherein the monomeric insulin analog is LysB28ProB29.
25. The process of Claim 23, wherein the monomeric insulin analog is AspB28.
26. The process of any one of Claims 23 through 25, wherein the buffer is arginine.
27. The formulation of any one of Claims 1 through 7 when made by the process of Claim 20.
28. The formulation of any one of Claims 8 through 11 when made by the process of Claim 23.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5308997P | 1997-06-13 | 1997-06-13 | |
US60/053,089 | 1997-06-13 | ||
PCT/US1998/012218 WO1998056406A1 (en) | 1997-06-13 | 1998-06-11 | Stable insulin formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2295140A1 true CA2295140A1 (en) | 1998-12-17 |
CA2295140C CA2295140C (en) | 2010-09-14 |
Family
ID=21981869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2295140A Expired - Lifetime CA2295140C (en) | 1997-06-13 | 1998-06-11 | Stable insulin formulations |
Country Status (31)
Country | Link |
---|---|
US (3) | US6034054A (en) |
EP (1) | EP0884053B1 (en) |
JP (1) | JP2002504908A (en) |
KR (1) | KR100597500B1 (en) |
CN (1) | CN1293916C (en) |
AR (1) | AR012894A1 (en) |
AT (2) | ATE226088T1 (en) |
AU (1) | AU734781B2 (en) |
BR (1) | BR9810116B1 (en) |
CA (1) | CA2295140C (en) |
CO (1) | CO4750643A1 (en) |
CZ (1) | CZ299637B6 (en) |
DE (2) | DE69808695T2 (en) |
DK (1) | DK0884053T3 (en) |
EA (1) | EA002880B1 (en) |
ES (2) | ES2185113T3 (en) |
HK (1) | HK1030747A1 (en) |
HU (1) | HUP0002877A3 (en) |
ID (1) | ID24310A (en) |
IL (1) | IL133348A0 (en) |
NO (1) | NO996131L (en) |
NZ (1) | NZ501382A (en) |
PE (1) | PE79099A1 (en) |
PL (1) | PL194244B1 (en) |
PT (2) | PT1283051E (en) |
SV (1) | SV1998000065A (en) |
TR (1) | TR199903036T2 (en) |
TW (1) | TW577753B (en) |
UA (1) | UA61109C2 (en) |
WO (1) | WO1998056406A1 (en) |
ZA (1) | ZA984697B (en) |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE79099A1 (en) * | 1997-06-13 | 1999-08-24 | Lilly Co Eli | STABLE INSULIN FORMULATIONS |
US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
ES2329220T3 (en) | 1999-01-06 | 2009-11-24 | Genentech, Inc. | MUTANT VARIANTS OF THE INSULIN SIMILAR GROWTH FACTOR (IGF) |
WO2000040613A1 (en) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
DE60005806T2 (en) | 1999-04-08 | 2004-08-05 | Genentech, Inc., South San Francisco | COMPOSITION BASED ON OPPOSITELY CHARGED POLYPEPTIDES |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6746853B1 (en) | 1999-05-19 | 2004-06-08 | Xencor, Inc. | Proteins with insulin-like activity useful in the treatment of diabetes |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US7022674B2 (en) * | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
US6734162B2 (en) | 2000-01-24 | 2004-05-11 | Minimed Inc. | Mixed buffer system for stabilizing polypeptide formulations |
EP1292324A2 (en) * | 2000-05-05 | 2003-03-19 | Novo Nordisk A/S | Critical illness neuropathy |
EP1282437B1 (en) | 2000-05-16 | 2008-03-19 | Genentech, Inc. | Treatment of cartilage disorders |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
AU2002248464A1 (en) | 2001-02-21 | 2002-09-12 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
DE10114178A1 (en) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
ES2298378T3 (en) | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | STABLE FORMULATION OF MODIFIED GLP-1. |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US20030068361A1 (en) * | 2001-10-09 | 2003-04-10 | Rimona Margalit | Liposome-encapsulated insulin formulations |
US20030199445A1 (en) * | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
ES2360182T3 (en) * | 2002-05-07 | 2011-06-01 | Novo Nordisk A/S | SOLUBLE FORMULATIONS THAT INCLUDE MONOMERIC INSULIN AND ACILATED INSULIN. |
DE10227232A1 (en) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Sour insulin preparations with improved stability |
KR101123113B1 (en) * | 2002-07-29 | 2012-03-15 | 쎄라피콘 에스.알.엘. | Nasal peptide pharmaceutical formulation |
ITMI20021684A1 (en) * | 2002-07-29 | 2004-01-29 | Therapicon Srl | PHARMACEUTICAL COMPOSITION OF NASAL PEPTIDE |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
PL1633391T3 (en) | 2003-06-03 | 2012-03-30 | Novo Nordisk As | Stabilized pharmaceutical peptide compositions |
PL3300721T3 (en) | 2003-11-20 | 2019-08-30 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
ES2618028T3 (en) | 2004-07-19 | 2017-06-20 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof. |
AU2005273968A1 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
EP2494983B1 (en) | 2004-11-12 | 2019-04-24 | Novo Nordisk A/S | Stable formulations of glp-1 |
US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
BRPI0519468A2 (en) | 2004-12-27 | 2009-01-27 | Silence Therapeutics Ag | coated lipid complexes and their use |
EP1862174A1 (en) * | 2005-03-02 | 2007-12-05 | Ajinomoto Co., Inc. | Inhibitor for insulin polymer formation |
JP2008542235A (en) * | 2005-05-25 | 2008-11-27 | ノボ・ノルデイスク・エー/エス | Stabilized polypeptide preparation |
US8097584B2 (en) * | 2005-05-25 | 2012-01-17 | Novo Nordisk A/S | Stabilized formulations of insulin that comprise ethylenediamine |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
US20100210506A1 (en) * | 2005-10-20 | 2010-08-19 | Mdrna, Inc. | Intranasal administration of rapid acting insulin |
EP1969004B1 (en) | 2005-12-28 | 2011-08-10 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
US8927015B2 (en) * | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
CA2649630C (en) * | 2006-04-20 | 2016-04-05 | Silence Therapeutics Ag | Lipoplex formulations for specific delivery to vascular endothelium |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
BRPI0711558A2 (en) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polymorphs |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
WO2007135117A2 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations |
US9023793B2 (en) * | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
US8114428B2 (en) * | 2007-03-08 | 2012-02-14 | Sbf Synthetic Bone Factory Gmbh | Methods for manufacturing a composition for treating bone and/or cartilage defects |
WO2008118387A2 (en) * | 2007-03-23 | 2008-10-02 | Wayne State University | Erythrocyte atp-release modulators |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
AU2008313248B2 (en) * | 2007-10-16 | 2012-04-26 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
PL2910570T3 (en) | 2008-03-18 | 2017-06-30 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
AR071175A1 (en) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO |
TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
ES2531657T3 (en) | 2008-05-01 | 2015-03-18 | Arecor Limited | Formulation of a protein |
TWI451876B (en) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | Pegylated insulin lispro compounds |
EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
KR20190016601A (en) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment for diabetes in patients inappropriate for metformin therapy |
ES2477552T3 (en) | 2008-09-08 | 2014-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
NZ592283A (en) | 2008-10-17 | 2012-09-28 | Sanofi Aventis Deutschland | Combination of an insulin and the GLP-1 agonist AVE0010 |
WO2010062308A1 (en) | 2008-10-28 | 2010-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
JP4959005B2 (en) | 2008-10-30 | 2012-06-20 | ノボ・ノルデイスク・エー/エス | Treatment of diabetes mellitus with insulin injections less than daily injection frequency |
JP2012512848A (en) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Salt forms of organic compounds |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AU2010208305A1 (en) | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
PE20120583A1 (en) | 2009-01-28 | 2012-05-19 | Smartcells Inc | CONJUGATE-BASED SYSTEMS FOR CONTROLLED PHARMACOLOGICAL DELIVERY |
EP2391216A4 (en) | 2009-01-28 | 2013-06-19 | Smartcells Inc | Exogenously triggered controlled release materials and uses thereof |
CA2750269A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Crystalline insulin-conjugates |
MX2011008562A (en) | 2009-02-12 | 2011-09-09 | Proyecto Biomedicina Cima Sl | Use of cardiotrophin- 1 for the treatment of metabolic diseases. |
AU2010217760B2 (en) | 2009-02-27 | 2015-04-09 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
US9250106B2 (en) | 2009-02-27 | 2016-02-02 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
WO2010107519A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
HUE027239T2 (en) * | 2009-06-26 | 2016-10-28 | Novo Nordisk As | Preparation comprising insulin, nicotinamide and arginine |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
MX2012005184A (en) | 2009-11-13 | 2012-06-08 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine. |
MX2012005186A (en) | 2009-11-13 | 2012-06-08 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine. |
KR20210033559A (en) | 2009-11-27 | 2021-03-26 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
CN101912600B (en) * | 2010-01-11 | 2014-01-29 | 杨国汉 | Method for improving stability of insulin in solution |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
WO2012015692A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
EP2598522A4 (en) | 2010-07-28 | 2014-11-12 | Smartcells Inc | Recombinant lectins, binding-site modified lectins and uses thereof |
WO2012015681A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
JP6199186B2 (en) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
DK2632478T3 (en) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
CN102188367B (en) * | 2011-01-05 | 2012-11-07 | 山东新时代药业有限公司 | Insulin glargine injecta and preparation method thereof |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
US20130345113A1 (en) * | 2011-07-13 | 2013-12-26 | Ronald E. Strohbehn | Method of Use of Activated Functional Proteins to Improve Animal Health |
CA2841552C (en) | 2011-07-15 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
SI2750699T1 (en) | 2011-08-29 | 2015-11-30 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
EP2773331B1 (en) * | 2011-10-31 | 2016-02-10 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
JP6735561B2 (en) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs |
BR112015011179A8 (en) | 2012-12-19 | 2019-10-01 | Wockhardt Ltd | stable aqueous pharmaceutical compositions comprising human insulin or an analogue or derivative thereof, their use and processes for their preparation |
CA2889162A1 (en) | 2012-12-26 | 2014-07-03 | Wockhardt Limited | Pharmaceutical composition |
TWI780236B (en) * | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
EP2970124B1 (en) | 2013-03-14 | 2019-05-22 | The Board of Trustees of the Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
AU2014247167B2 (en) | 2013-04-03 | 2018-11-22 | Sanofi | Treatment of diabetes mellitus by long–acting formulations of insulins |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
WO2015008169A2 (en) * | 2013-07-04 | 2015-01-22 | Insuline Medical Ltd. | Device, system and method for delivery of a long-acting drug |
EP3052134B1 (en) | 2013-10-04 | 2021-05-05 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
AR098168A1 (en) | 2013-10-25 | 2016-05-04 | Sanofi Sa | STABLE FORMULATION OF GLULISINE INSULIN |
EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CN114939156A (en) | 2014-01-09 | 2022-08-26 | 赛诺菲 | Stabilized pharmaceutical formulations of insulin aspart |
JP6944780B2 (en) * | 2014-01-13 | 2021-10-06 | サーマリン インコーポレイテッド | Fast-acting insulin preparation and drug delivery system |
ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
JP6970615B2 (en) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Insulin glargine / lixisenatide fixed ratio prescription |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
CN105535942B (en) * | 2016-01-28 | 2017-07-28 | 通化东宝药业股份有限公司 | A kind of preparation method of insulin lispro protamine sulfate preparation and its insulin lispro protamine sulfate preparation of preparation |
EP3419649A1 (en) * | 2016-02-25 | 2019-01-02 | Wockhardt Limited | Pharmaceutical composition of insulin glargine and amino acids |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CN110087674B (en) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | Pharmaceutical composition containing insulin |
SG11202003754YA (en) | 2017-05-16 | 2020-05-28 | Bhamis Research Laboratory Pvt Ltd | High concentration protein formulations with reduced viscosity |
PE20211202A1 (en) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | COMPOSITIONS OF GLP-1 AND ITS USES |
US11413352B2 (en) | 2017-12-18 | 2022-08-16 | Merck, Sharp & Dohme LLC | Conjugate based systems for controlled insulin delivery |
EP3727424A4 (en) | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
CN110063932A (en) * | 2019-04-12 | 2019-07-30 | 浙江大学 | A kind of slow releasing composition preparation of polypeptide protein class drug and preparation method thereof |
EP4106724A1 (en) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
CR20220555A (en) | 2020-03-31 | 2023-01-23 | Protomer Tech Inc | Conjugates for selective responsiveness to vicinal diols |
AU2021382599A1 (en) | 2020-11-19 | 2023-06-22 | Protomer Technologies Inc. | Aromatic boron-containing compounds and insulin analogs |
WO2023017537A1 (en) | 2021-08-12 | 2023-02-16 | Celagenex Research (India) Pvt. Ltd. | Oral algal oil based gastro-intestinal tract permeable peptide composition |
US20230374045A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1285023A (en) | 1968-08-09 | 1972-08-09 | Novo Terapeutisk Labor As | Improvements in or relating to injectable insulin preparations |
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
JPS5767548A (en) * | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
AU550068B2 (en) * | 1981-03-10 | 1986-02-27 | Novo Nordisk A/S | Zinc insulin stabilized with calcium or magnesium salts |
FI78616C (en) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Process for preparing an infused stabilized insulin solution having an elevated zinc content |
US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
DK179286D0 (en) * | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | INSULIN PREPARATION |
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
AR002976A1 (en) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED |
PE79099A1 (en) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | STABLE INSULIN FORMULATIONS |
WO1999034821A1 (en) * | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
-
1998
- 1998-06-01 PE PE1998000437A patent/PE79099A1/en not_active Application Discontinuation
- 1998-06-01 AR ARP980102554A patent/AR012894A1/en active IP Right Grant
- 1998-06-01 CO CO98030641A patent/CO4750643A1/en unknown
- 1998-06-01 ZA ZA9804697A patent/ZA984697B/en unknown
- 1998-06-08 SV SV1998000065A patent/SV1998000065A/en not_active Application Discontinuation
- 1998-06-10 TW TW087109241A patent/TW577753B/en not_active IP Right Cessation
- 1998-06-11 ID IDW991511A patent/ID24310A/en unknown
- 1998-06-11 KR KR1019997011715A patent/KR100597500B1/en not_active IP Right Cessation
- 1998-06-11 NZ NZ501382A patent/NZ501382A/en not_active IP Right Cessation
- 1998-06-11 TR TR1999/03036T patent/TR199903036T2/en unknown
- 1998-06-11 EA EA200000014A patent/EA002880B1/en not_active IP Right Cessation
- 1998-06-11 IL IL13334898A patent/IL133348A0/en not_active IP Right Cessation
- 1998-06-11 AU AU78377/98A patent/AU734781B2/en not_active Expired
- 1998-06-11 BR BRPI9810116-1A patent/BR9810116B1/en not_active IP Right Cessation
- 1998-06-11 CN CNB988081229A patent/CN1293916C/en not_active Expired - Lifetime
- 1998-06-11 CZ CZ0445199A patent/CZ299637B6/en not_active IP Right Cessation
- 1998-06-11 HU HU0002877A patent/HUP0002877A3/en unknown
- 1998-06-11 CA CA2295140A patent/CA2295140C/en not_active Expired - Lifetime
- 1998-06-11 JP JP50323799A patent/JP2002504908A/en active Pending
- 1998-06-11 WO PCT/US1998/012218 patent/WO1998056406A1/en active Application Filing
- 1998-06-11 US US09/096,247 patent/US6034054A/en not_active Expired - Lifetime
- 1998-06-11 PL PL98337324A patent/PL194244B1/en unknown
- 1998-06-12 DK DK98304661T patent/DK0884053T3/en active
- 1998-06-12 AT AT98304661T patent/ATE226088T1/en active
- 1998-06-12 PT PT02022956T patent/PT1283051E/en unknown
- 1998-06-12 EP EP98304661A patent/EP0884053B1/en not_active Expired - Lifetime
- 1998-06-12 ES ES98304661T patent/ES2185113T3/en not_active Expired - Lifetime
- 1998-06-12 PT PT98304661T patent/PT884053E/en unknown
- 1998-06-12 DE DE69808695T patent/DE69808695T2/en not_active Expired - Lifetime
- 1998-06-12 DE DE69834956T patent/DE69834956T2/en not_active Expired - Lifetime
- 1998-06-12 ES ES02022956T patent/ES2264713T3/en not_active Expired - Lifetime
- 1998-06-12 AT AT02022956T patent/ATE329612T1/en active
- 1998-11-06 UA UA99126744A patent/UA61109C2/en unknown
-
1999
- 1999-11-29 US US09/450,794 patent/US6551992B1/en not_active Expired - Lifetime
- 1999-12-10 NO NO996131A patent/NO996131L/en not_active Application Discontinuation
-
2001
- 2001-03-07 HK HK01101663A patent/HK1030747A1/en not_active IP Right Cessation
-
2002
- 2002-10-03 US US10/264,176 patent/US6906028B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2295140A1 (en) | Stable insulin formulations | |
US6734162B2 (en) | Mixed buffer system for stabilizing polypeptide formulations | |
CA2441260C (en) | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability | |
US20180036411A1 (en) | Stable Formulation of Insulin Glulisine | |
WO2001032158A3 (en) | Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent | |
EP1808438A3 (en) | Purification and stabilization of peptide and proteins in pharmaceutical agents | |
AU5909498A (en) | Formulations for amylin agonist peptides | |
JP2006193536A (en) | Stable, aqueous alpha interferon solution formulation | |
CN101351219A (en) | Stable formulations containing enhancing proportions of gamma- and alpha-interferons | |
EA008308B1 (en) | Liquid stabilized protein formulations in coated pharmaceutical containers | |
CA2389928A1 (en) | Method for treating diabetes | |
RU2242242C2 (en) | Preparative form of stable aqueous solution of interferon, method for its preparing and using | |
JPH01287041A (en) | Sustained release preparation | |
IL138221A (en) | Formulations for protection of peg-interferon alpha conjugates | |
HRP20020159A2 (en) | Multi-dose erythropoietin formulations | |
Zheng et al. | Heat sterilization of peritoneal dialysis solutions influences ingestive behavior in non-uremic rats | |
McKeage et al. | Spotlight on insulin glargine in type 1 and 2 diabetes mellitus | |
SK284306B6 (en) | Topical preparation for introducing peptidaceous pharmacons in living organisms | |
JP6920471B2 (en) | Insulin composition that acts quickly | |
CN113995833A (en) | Application of adenosine deaminase and modifier thereof in preparation of diabetic wound repair drugs | |
Bergan et al. | Temocillin penetration of peripheral lymph | |
JP2004035408A (en) | Stable composition comprising tezacitabine | |
JPH1045581A (en) | Agent for suppressing lowering of neutrophilic function or infection protecting agent | |
WO2003043537A1 (en) | Improvements in curing aids with tetrasilver tetroxide molecular crystal devices | |
CN103655468A (en) | Fusion protein Exendin-4-HSA solution stabilizing preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20180611 |